Beulah Ji

机构：GlaxoSmithKline (China) · ORCID：0000-0002-9944-348X

发表论文 44 篇 · 总被引 2814 次 · h-index 17

代表论文

• Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis (2020 · New England Journal of Medicine · 被引 1032)
• Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response (2012 · Annals of the Rheumatic Diseases · 被引 415)
• A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis (2021 · Kidney International · 被引 214)
• Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial (2020 · Annals of the Rheumatic Diseases · 被引 204)
• Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study (2019 · Arthritis & Rheumatology · 被引 141)
• Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus (2019 · Arthritis & Rheumatology · 被引 109)